Clinical Trial Update: Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML [Phase 1]

View source ↗

Summary

A Phase I study of the selective nuclear export inhibitor KPT-330 (selinexor) in children with relapsed or refractory acute lymphoblastic leukemia and acute mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelogenous Leukemia

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING